Foghorn Therapeutics
FHTX
47 hedge funds and large institutions have $338M invested in Foghorn Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more capital invested
Capital invested by funds: $255M → $338M (+$83.2M)
21% more funds holding
Funds holding: 39 → 47 (+8)
0.85% more ownership
Funds ownership: 64.88% → 65.73% (+0.85%)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
Top Buyers
| 1 |
KCM
Kingdon Capital Management
New York
|
+$2.28M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.73M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$754K |
| 4 |
JGC
J. Goldman & Co
New York
|
+$747K |
| 5 |
State Street
Boston,
Massachusetts
|
+$394K |
Top Sellers
FHTX Hedge Fund Activity: Q3 2021 in Review
47 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2021, worth a combined $338M — up 33% from $255M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new FHTX positions and 3 closed out — a net gain of 8 holders — while 10 added to existing stakes and 14 trimmed.
The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $2.28M. The largest seller was Millennium Management, cutting an estimated $1.14M.
- 47 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2021, up from 39 in Q2 2021.
- Funds reported $338M of Foghorn Therapeutics stock for Q3 2021, up 33% quarter-over-quarter.
- 11 funds opened new Foghorn Therapeutics positions in Q3 2021 and 3 closed out, a net change of +8 holders.
- The largest Foghorn Therapeutics buyer in Q3 2021 was Kingdon Capital Management, an estimated $2.28M added.
- The largest Foghorn Therapeutics seller in Q3 2021 was Millennium Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q3 2021.